Meeting
2015 Gastrointestinal Cancers Symposium
Final results of a phase Ib study of gemcitabine plus PEGPH20 in patients with stage IV previously untreated pancreatic cancer.
Authors
Sunil R. Hingorani
Fred Hutchinson Cancer Research Center, Seattle, WA
Sunil R. Hingorani , William Proctor Harris , Joseph Thaddeus Beck , Boris A. Berdov , Stephanie Ann Wagner , Eduard M. Pshevlotsky , Sergei Tjulandin , Oleg Gladkov , Randall F. Holcombe , Ping Jiang , Craig E. Devoe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 359)
DOI
10.1200/jco.2015.33.3_suppl.359
Abstract #
359
Poster Bd #
C28
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer.
First Author: Sunil R. Hingorani
Poster
2022 ASCO Annual Meeting
Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.
First Author: Tara Elisabeth Seery
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer.
First Author: Gayle S. Jameson
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory biomarker results from early investigation of PEGPH20 in combination with gemcitabine (Gem) in patients with pancreatic cancer (PDA).
First Author: Sunil R. Hingorani